A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single-Dose, Four-Way Crossover Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single-Dose, Four-Way Crossover Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Moxifloxacin
  • Indications B cell lymphoma; Breast cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Graft-versus-host disease; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development; Pharmacyclics
  • Most Recent Events

    • 01 Dec 2017 Results assessing effect of ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization published in the Cancer Chemotherapy and Pharmacology
    • 01 Dec 2017 Status changed to discontinued.
    • 27 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top